Search Results - Mark M Awad

Reply to Cortellini A by Biagio Ricciuti, MD, Mark M. Awad, MD, PhD

Get full text

Immune-related response assessment during PD-1 inhibitor therapy in advanced non-small-cell lung cancer patients by F. Stephen Hodi, Pasi A. Janne, Mark M. Awad, Mizuki Nishino, Nikhil H. Ramaiya, Emily S. Chambers, Anika E. Adeni, Hiroto Hatabu

Get full text

Corrigendum: Selective Histone Deacetylase Inhibitor ACY-241 (Citarinostat) Plus Nivolumab in Advanced Non-Small Cell Lung Cancer: Results From a Phase Ib Study by Mark M. Awad, Yvan Le Bruchec, Brian Lu, Jason Ye, Julie Ann Miller, Patrick H. Lizotte, Megan E. Cavanaugh, Amanda J. Rode, Calin Dan Dumitru, Alexander Spira

Get full text

Plasma IL-6 changes correlate to PD-1 inhibitor responses in NSCLC by Mariano Severgnini, Biagio Ricciuti, Alissa Keegan, Padric Garden, Limor Cohen, Reiko Nishihara, Anika Adeni, Cloud Paweletz, Julianna Supplee, Pasi A Jänne, Mark M Awad, David R Walt

Get full text

Mechanistic patterns and clinical implications of oncogenic tyrosine kinase fusions in human cancers by Taek-Chin Cheong, Ahram Jang, Qi Wang, Giulia C. Leonardi, Biagio Ricciuti, Joao V. Alessi, Alessandro Di Federico, Mark M. Awad, Maria K. Lehtinen, Marian H. Harris, Roberto Chiarle

Get full text

Additional impact of genetic ancestry over race/ethnicity to prevalence of KRAS mutations and allele-specific subtypes in non-small cell lung cancer by Xinan Wang, Kangcheng Hou, Biagio Ricciuti, Joao V. Alessi, Xihao Li, Federica Pecci, Rounak Dey, Jia Luo, Mark M. Awad, Alexander Gusev, Xihong Lin, Bruce E. Johnson, David C. Christiani

Get full text

Variation in targetable genomic alterations in non-small cell lung cancer by genetic ancestry, sex, smoking history, and histology by Elio Adib, Amin H. Nassar, Sarah Abou Alaiwi, Stefan Groha, Elie W. Akl, Lynette M. Sholl, Kesi S. Michael, Mark M. Awad, Pasi A. Jӓnne, Alexander Gusev, David J. Kwiatkowski

Get full text

192 Clinicopathologic, genomic and immunophenotypic features and outcomes to immune checkpoint inhibitors in patients with mucinous lung adenocarcinoma by Mizuki Nishino, Biagio Ricciuti, Scott J Rodig, Joao V Alessi, Jia Luo, Mark M Awad, Bruce E Johnson, Federica Pecci, Alessandro Di Federico, Malini M Gandhi, Lynette M Sholl, Maisam Makarem, Emma Voligny, Tom Nguyen, Danielle Haradon

Leptomeningeal Response to Capmatinib After Progression on Crizotinib in a Patient With MET Exon 14–Mutant NSCLC by Paola Cravero, MD, Nuno Vaz, MD, Biagio Ricciuti, MD, Sarah E. Clifford, MPH, Gianluca DiUbaldi, BS, BA, Dawn Drevers, RN, Kaitlin Morton, BS, Rebecca E. Rivenburgh, BS, Mizuki Nishino, MD, MPH, Mark M. Awad, MD, PhD

Get full text

Neoadjuvant atezolizumab + chemotherapy for resectable NSCLC: 3-year clinical update of phase II clinical trial results and translational findings by Benjamin Izar, Justin F Gainor, Mark M Awad, Codruta Chiuzan, Anjali Saqi, Catherine A Shu, Katja Schulze, Brian S Henick, Naiyer A Rizvi, Samyukta Mallick, Yohanna Georgis, Peter D Koch, Stephanie Izard, Robert F Garofano, Cheryl V Wong, Jessica Grindheim, Joshua R Sonett, Alison M Taylor

Get full text

Multi-institutional analysis of aneuploidy and outcomes to chemoradiation and durvalumab in stage III non-small cell lung cancer by Biagio Ricciuti, Joao V Alessi, Mark M Awad, Arielle Elkrief, Jamie E Chaft, Bruce E Johnson, Xinan Wang, Allison L Richards, Federica Pecci, Alessandro Di Federico, Adam J Schoenfeld, Malini M Gandhi, Adam Price, Emily S Lebow, Patricia Mae G Santos, Maria Thor, Andreas Rimner, Daniel R Gomez, Narek Shaverdian

Get full text

PD-L1, Tumor Mutational Burden, and Outcomes in NSCLC With Brain Metastases: A Brief Report by Elio Adib, MD, Amin H. Nassar, MD, Elias Bou Farhat, MD, Shyam K. Tanguturi, MD, Rifaquat M. Rahman, MD, Daphne A. Haas-Kogan, MD, MBA, Wenya Linda Bi, MD, PhD, Omar Arnaout, MD, Patrick Y. Wen, MD, David J. Kwiatkowski, MD, PhD, Mark M. Awad, MD, PhD, Ayal A. Aizer, MD

Get full text

RAS-ON inhibition overcomes clinical resistance to KRAS G12C-OFF covalent blockade by Marie-Julie Nokin, Alessia Mira, Enrico Patrucco, Biagio Ricciuti, Sophie Cousin, Isabelle Soubeyran, Sonia San José, Serena Peirone, Livia Caizzi, Sandra Vietti Michelina, Aurelien Bourdon, Xinan Wang, Daniel Alvarez-Villanueva, María Martínez-Iniesta, August Vidal, Telmo Rodrigues, Carmen García-Macías, Mark M. Awad, Ernest Nadal, Alberto Villanueva, Antoine Italiano, Matteo Cereda, David Santamaría, Chiara Ambrogio

Get full text

JNJ-64041757 (JNJ-757), a Live, Attenuated, Double-Deleted Listeria monocytogenes–Based Immunotherapy in Patients With NSCLC: Results From Two Phase 1 Studies by Julie R. Brahmer, MD, Melissa L. Johnson, MD, Manuel Cobo, MD, PhD, Santiago Viteri, MD, Juan Coves Sarto, MD, Ammar Sukari, MD, Mark M. Awad, MD, PhD, Ravi Salgia, MD, PhD, Vali A. Papadimitrakopoulou, MD, Arun Rajan, MD, Nibedita Bandyopadhyay, PhD, Alicia J. Allred, PhD, Mark Wade, MA, Gary E. Mason, MD, Enrique Zudaire, PhD, Roland E. Knoblauch, MD, PhD, Nicole Stone, PhD, Matthew V. Lorenzi, PhD, Raffit Hassan, MD

Get full text

Association Between Immune-Related Adverse Events and Clinical Outcomes to Programmed Cell Death Protein 1/Programmed Death-Ligand 1 Blockade in SCLC by Biagio Ricciuti, MD, Abdul Rafeh Naqash, MD, Jarushka Naidoo, MD, Kartik Sehgal, MD, Adam Miller, MD, Kenneth Kehl, MD, MPH, Deepti Venkatraman, MPH, Jacob Sands, MD, Giuseppe Lamberti, MD, Gonzalo Recondo, MD, PhD, Jiajia Zhang, MD, Shravanti Macherla, MD, Sameer Baig, MD, Paul Walker, MD, Deepa Rangachari, MD, Justin F. Gainor, MD, Daniel B. Costa, MD, Naiyer Rizvi, MD, Lynette M. Sholl, MD, Mizuki Nishino, MD, MPH, Brian Henick, MD, Anna F. Farago, MD, PhD, Mark M. Awad, MD, PhD

Get full text

Prognostic effect of body mass index in patients with advanced NSCLC treated with chemoimmunotherapy combinations by James Artingstall, Alex Friedlaender, Alfredo Addeo, Judith Cave, Massimo Di Maio, Samuel Chan, Alessio Cortellini, Marcello Tiseo, Biagio Ricciuti, Francesco Facchinetti, Benjamin Besse, Joao V Alessi, Mark M Awad, David J Pinato, Giuseppe L Banna, Giuseppe Lamberti, Margarita Majem, Frank Aboubakar Nana, Charles Comins, Thomas Newsom-Davis, Victor R Vaz, Laura Mezquita, Davide Soldato, Filippo G Dall’Olio, Sethupathi Muthuramalingam, Aida Piedra, Elisa Andrini, Teresa Gorría, Delphine Hoton, Lacroix Valerie, Andrea Caglio, Hayley McKenzie, Joanne S Evans, Antonio D'Alessio, Claudia A M Fulgenzi

Get full text

Patient-Reported Health-Related Quality of Life in KEYNOTE-604: Pembrolizumab or Placebo Added to Etoposide and Platinum as First-Line Therapy for Extensive-Stage SCLC by Hye Ryun Kim, MD, PhD, Mark M. Awad, MD, PhD, Alejandro Navarro, MD, Maya Gottfried, MD, Solange Peters, MD, PhD, Tibor Csőszi, MD, Parneet K. Cheema, MD, Delvys Rodriguez-Abreu, MD, PhD, Mirjana Wollner, MD, James Chih-Hsin Yang, MD, PhD, Julien Mazieres, MD, PhD, Francisco J. Orlandi, MD, Alexander Luft, MD, PhD, Mahmut Gümüş, MD, Terufumi Kato, MD, Gregory P. Kalemkerian, MD, Yiwen Luo, PhD, Melissa L. Santorelli, PhD, MPH, M. Catherine Pietanza, MD, Charles M. Rudin, MD, PhD

Get full text

218 Prospective spatial immune cell profiling identifies features of the tumor-immune microenvironment associated with genomic alterations and patient survival in a 2,023 patient p... by Sara M Tolaney, James Lindsay, Michael Manos, Biagio Ricciuti, Anita Giobbie-Hurder, Scott J Rodig, Joao V Alessi, Mark M Awad, Sandro Santagata, Bruce E Johnson, Glenn J Hanna, Elio Adib, Jason Weirather, Xinan Wang, Bijaya Sharma, Kathleen Pfaff, Kristen D Felt, William Lotter, Panagiotis Konstantinopoulos, Madison Turner, Federica Pecci, Emma L Welsh, Stephanie M Jones, Jennifer O Altreuter, Ian D Dryg, Alessandro Di Federico, Malini M Gandhi, Sabrina J Chan, Marta Holovatska, Melissa E Hughes, O’Meara Tess A, Neal I Lindeman, Jennifer Curtis, Peter K Sorger, Ethan Cerami, Lynette M Sholl, Jonathan A Novak

Brief Report: Clinical Characteristics and Outcomes of Patients With Thoracic SMARCA4-Deficient Undifferentiated Tumors by Alissa J. Cooper, MD, Andrea Arfe, PhD, Biagio Ricciuti, MD, Andréanne Gagné, MD, PhD, Lynette M. Sholl, MD, Alessandro Di Federico, MD, Mark M. Awad, MD, PhD, Mihaela Aldea, MD, PhD, Maria Rosa Ghigna, MD, Miruna Grecea, MD, Phoebe Clark, MS, Jamie E. Chaft, MD, Mark G. Kris, MD, Gregory J. Riely, MD, Charles M. Rudin, MD, PhD, Ibiayi Dagogo-Jack, MD, Mari Mino-Kenudson, MD, Lingzhi Hong, MD, PhD, Neda Kalhor, MD, Natalie Vokes, MD, Anita Bowman, MS, Soo-Ryum Yang, MD, Natasha Rekhtman, MD, PhD, Adam J. Schoenfeld, MD

Get full text

Three-Year Overall Survival Outcomes and Correlative Analyses in Patients With NSCLC and High (50%–89%) Versus Very High (≥90%) Programmed Death-Ligand 1 Expression Treated With Fi... by Biagio Ricciuti, MD, PhD, Arielle Elkrief, MD, Jessica Lin, MD, Jianjun Zhang, MD, Joao V. Alessi, MD, Giuseppe Lamberti, MD, PhD, Malini Gandhi, MD, Alessandro Di Federico, MD, Federica Pecci, MD, Xinan Wang, PhD, Maisam Makarem, MD, PhD, Cassio Murilo Hidalgo Filho, MD, Teresa Gorria, MD, Arushi Saini, BS, Cindy Pabon, MD, James Lindsay, PhD, Kathleen L. Pfaff, PhD, Emma L. Welsh, BS, Mizuki Nishino, MD, Lynette M. Sholl, MD, Scott Rodig, MD, Saadettin Kilickap, MD, Petra Rietschel, MD, Debra AG. McIntyre, PhD, Jean-Francois Pouliot, MD, Mehmet Altan, MD, Justin F. Gainor, MD, John V. Heymach, MD, Adam J. Schoenfeld, MD, Mark M. Awad, MD, PhD

Get full text